Monitor the first trading days on Nasdaq for liquidity and price discovery. The key catalyst remains the first commercial launch of BreastCheck in H2 2026 and the company's ability to generate revenue or secure additional financing given the minimal cash runway.
Price Chart
Executive Summary
Davion Healthcare Plc announced its ordinary shares are expected to commence trading on the Nasdaq Global Market on October 22, 2026, under ticker 'DAVI'. The company also appointed Glenn Williams as CEO and Jeremy North as COO, established an Operational Directorate, and disclosed annual salaries for incoming roles. This is a structural milestone for a pre-revenue company with only €1,058 in cash per the prior 20-F, and the Nasdaq listing provides a public market platform but does not change the fundamental cash runway or commercial risk.
Key Facts
- Ordinary shares expected to commence trading on Nasdaq Global Market on Thursday, October 22, 2026, under ticker 'DAVI'.
- Glenn Williams appointed CEO and Jeremy North appointed COO, effective upon commencement of trading.
- Jack Kaye, current CEO, will become Chairman; Sir Eric Peacock steps down as Chairman but remains as Non-Executive Director.
- Annual salaries: Jack Kaye (Chairman) US$600,000, Glenn Williams (CEO) US$516,000, Jeremy North (COO) US$420,000.
- Operational Directorate established as principal executive management body, led by CEO Glenn Williams.
- Davion recently established Davion Healthcare Finance Ltd and launched a £30 million five-year senior secured bond to support acquisition programme.
- Per prior 20-F (April 2026), Davion had only €1,058 in cash at year-end 2025 and relied on CEO advances and a letter of support from Malbrite Ltd for the next 12 months.
- BreastCheck is FDA-registered but not a replacement for mammography or clinical diagnosis; first commercial launch expected H2 2026 per prior 20-F.
Financial Impact
No financial results reported. Nasdaq listing provides access to public equity markets but does not change the pre-revenue status or cash position of €1,058 as of FY2025 year-end. The £30 million bond provides dedicated acquisition financing but is a debt obligation.
Risk Factors
- Pre-revenue company with only €1,058 in cash per the prior 20-F, relying on CEO advances and a letter of support for the next 12 months.
- Nasdaq listing does not guarantee capital raising; the company may need to issue equity or debt, causing dilution.
- BreastCheck is FDA-registered but not a replacement for mammography; commercial adoption is unproven.
- Material weakness in internal controls and need for restatement of prior financials disclosed in the prior 20-F.
- The £30 million bond is a debt obligation that must be serviced, adding financial risk.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001683168-26-007973 |
| Document: davion_6k.htm | 0001683168-26-007973 |
| Document: 0001683168-26-007973-index-headers.html | 0001683168-26-007973 |
| Document: 0001683168-26-007973-index.html | 0001683168-26-007973 |
| Document: 0001683168-26-007973.txt | 0001683168-26-007973 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | Press Release | $5.10 | awaiting T+20 | — | $6.00 (+17.65%) |
Oct 20, 2026 5d ago | 6-K | — | awaiting T+20 | — | — |
Sep 15, 2026 5w ago | 6-K | — | awaiting T+20 | — | — |
Apr 30, 2026 25w ago | 20-F | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers